Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection screening in newly arrived Afghan sanctuary seekers - a family-centred approach.

BMC health services research·2026
Same author

'Respond'-A novel approach to healthcare delivery for people seeking asylum.

PLOS global public health·2026
Same author

Catch-Up Screening to Improve Detection of Congenital Chagas Disease in a Nonendemic Setting.

The American journal of tropical medicine and hygiene·2026
Same author

Epidemiology and management of nitroimidazole-refractory giardiasis.

Journal of travel medicine·2026
Same author

Failure to thrive: a delayed presentation of congenital diaphragmatic hernia.

BMJ case reports·2025
Same author

A qualitative study exploring the use of interpreters in a healthcare setting for children and young people seeking asylum and refugees.

BMC health services research·2025

Related Experiment Video

Updated: Jun 5, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Mannose-binding lectin in HIV infection.

Sarah Eisen1, Agnieszka Dzwonek, Nigel J Klein

  • 1Department of Infectious Diseases & Microbiology, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK, Tel.: +44 207 905 2215; ; s.eisen@ich.ucl.ac.uk.

Future Virology
|January 11, 2011
PubMed
Summary

Human immunodeficiency virus (HIV) infection poses a global health challenge. Mannose-binding lectin (MBL) interactions offer potential immunomodulation targets for novel HIV therapies.

More Related Videos

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Related Experiment Videos

Last Updated: Jun 5, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • Human immunodeficiency virus (HIV) infection is a major global health concern with high mortality.
  • Current antiretroviral therapies face challenges including accessibility, drug resistance, and side effects.
  • HIV profoundly impacts the human immune system, complicating treatment and disease progression.

Purpose of the Study:

  • To investigate the role of mannose-binding lectin (MBL) in HIV infection.
  • To explore MBL as a potential target for immunomodulation in HIV treatment.

Main Methods:

  • The study focuses on the complex interactions between HIV and the innate and humoral immune systems.
  • Emphasis is placed on the function of MBL, a key component of the innate immune system.

Main Results:

  • Mannose-binding lectin (MBL) plays a significant role in host-virus interactions.
  • MBL may influence host susceptibility, HIV pathogenesis, disease progression, and variability in host response.

Conclusions:

  • Understanding and manipulating MBL response could lead to novel immunomodulatory strategies for HIV infection.
  • Combining MBL-targeted therapies with highly active antiretroviral therapy (HAART) may offer a new therapeutic approach for HIV.